Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.33 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28287132 | 0.98 | GABRP (0.32) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Ammonia Solution, Strong SCHEMBL27921266 | 0.79 | EEF2K (0.37) | — | |
| SCHEMBL18774938 | 0.78 | TAAR1 (0.32) | — | |
| SCHEMBL331189 | 0.77 | — | — | |
| SCHEMBL31374862 | 0.77 | — | — | |
| SCHEMBL1887395 | 0.77 | — | — | |
| SCHEMBL29191349 | 0.74 | — | — | |
| SCHEMBL181553 | 0.74 | — | — | |
| SCHEMBL8733040 | 0.74 | — | — | |
| SCHEMBL752841 | 0.74 | HDAC4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-03-10 | — | — | US | claimed |
| CN-111514286-B | Zika virus E protein conjugate vaccine and preparation method thereof | 中国科学院过程工程研究所 | 2022-03-08 | — | — | CN | claimed |
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2021-07-29 | — | — | US | claimed |
| EP-3703666-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | Universidade de Santiago de Compostela (ES) | 2020-09-09 | — | — | EP | claimed |
| CN-109651224-A | A kind of fluorescence protein crosslinking agent and preparation method thereof | 苏州昊帆生物股份有限公司 | 2019-04-19 | — | — | CN | claimed |
| US-20260102500-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING | SMARTDYELIVERY GMBH (DE) | 2026-04-16 | — | — | US | disclosed |
| EP-4720089-A1 | COMPOSITIONS AND METHODS FOR IMAGING AND TREATING ENDOMETRIOSIS | Endomet Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250354056-A1 | POLYMER DOTS | BIO RAD LABORATORIES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | SMARTDYELIVERY GMBH (DE) | 2025-11-18 | — | — | US | disclosed |
| EP-4638489-A1 | PROTEIN-BASED CONJUGATION CARRIERS | Ablynx N.V. (BE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4601648-A2 | ACRIDINIUM COMPOUNDS WITH FUSED HETEROCYCLES | Siemens Healthcare Diagnostics Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-3962491-B1 | INTRACELLULAR DELIVERY OF ANTI-KRAS ANTIBODIES FORMULATED INTO NANOCAPSULES | UNIV SANTIAGO COMPOSTELA (ES) | 2025-08-06 | — | — | EP | disclosed |
| WO-2006124737-A2 | MOLECULAR CONSTRUCTS SUITABLE FOR TARGETED CONJUGATES | TAPESTRY PHARMACEUTICALS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060154251-A1 | Carboxamide-substituted dyes for analytical applications | ATTO-TEC GMBH (DE) | 2006-07-13 | — | — | US | disclosed |
| US-20050233462-A1 | Reagents and a method for saturation labelling of proteins | GLOBAL LIFE SCIENCES SOLUTIONS GERMANY GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| CN-1650168-A | Reagents and methods for saturation labelling of proteins | AMOSEN BIOLOG SCIENCE BRITISH (GB) | 2005-08-03 | — | — | CN | disclosed |
| EP-1520176-A1 | REAGENTS AND A METHOD FOR SATURATION LABELLING OF PROTEINS | Amersham Biosciences UK Limited (GB) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005933-A1 | REAGENTS AND A METHOD FOR SATURATION LABELLING OF PROTEINS | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
| US-6103236-A | IN WHICH A COMPOUND HAVING AN AFFINITY FOR A TARGET CELL IS BOUND TO A TOXIN THROUGH A SPACER CONSISTING ESSENTIALLY OF POLYALKYLENE GLYCOL AND A DIPEPTIDE. | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0867190-A1 | NOVEL TOXIN COMPLEX | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233462-A1 | Reagents and a method for saturation labelling of proteins | SET, IK, MRPS22 | GABRP 3336/4885GABRD 4019/4885GABRA1 3964/4885 |
| US-20210228494-A1 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | LNPEP, CLIC1, CLSPN | GABRP 1254/4885GABRD 3428/4885GABRA1 2361/4885 |
| US-20060154251-A1 | Carboxamide-substituted dyes for analytical applications | CPS1, CYCS, PFAS | GABRP 1543/4885GABRD 3213/4885GABRA1 1272/4885 |
| US-20220071917-A9 | DRUG DELIVERY SYSTEMS AND METHODS COMPRISING POLYSIALIC ACID AND/OR OTHER POLYMERS | LNPEP, CLIC1, CLSPN | GABRP 1254/4885GABRD 3428/4885GABRA1 2361/4885 |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | PRKCH, PRKCZ, PIKFYVE | GABRP 1317/4885GABRD 3902/4885GABRA1 4497/4885 |
| US-20260102500-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING | PRKCE, PRKCI, PRKCZ | GABRP 1510/4885GABRD 3973/4885GABRA1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.